
About Styrax
Styrax is a Healthcare company based in Hyderabad (India) founded in 1995. Styrax has raised $2.75 million across 1 funding round from investors including Arora Life Sciences. The company has 260 employees. Styrax was last valued at $8.8 million in July 2017. Its Indian entity Styrax Pharma Private Limited reported revenue of βΉ260 Cr. Styrax offers products and services including APIs and Intermediates. Its focus areas include Traditional Pharmaceuticals.
Company details
Manufacturer supplier of active pharmaceutical ingredients and intermediates. It offers a diverse range of active pharmaceutical ingredients and intermediates include Abacavir Sulphate, Emtricitabine USP, Lamivudine, Tenofovir Disoproxil Fumarate, Fluconazole, Itraconazole, Levocetirizine Dihydrochloride, Rifaximin, Duloxetine Hydrochloride and Eltrombopag.
- Headquarters Hyderabad, India
- Employees 260
- Stage Minicorn
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website styraxpharma.com
- Social Facebook
- Legal Name Styrax Pharma Private Limited
- Date of Incorporation 10 Jul, 1995
- Jurisdiction Visakhapatnam, Andhra Pradesh, India
- Annual Revenue₹260 Cr
FY 2024 · +4% YoY
- Net Profit₹9.16 Cr
FY 2024 · 4% margin
- EBITDA₹29.31 Cr
FY 2024 · 11% margin
- Total Equity Funding$2.75M (USD)
in 1 rounds
- Latest Funding Round$2.75M (USD), Series A
Jul 2017
- Employee Count260
Associated legal entities of Styrax
Styrax operates through Styrax Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2024) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Styrax Pharma Private Limited CIN U24230AP1995PTC098146 | Active | 10 Jul 1995 | Visakhapatnam, Andhra Pradesh | ₹260 Cr | 260 | 4 | View details |
Products & Services of Styrax
Styrax offers a comprehensive portfolio of products and services, including APIs and Intermediates.
APIs are produced by Styrax Pharma, including various active pharmaceutical ingredients that are manufactured in accordance with quality standards.
Intermediates are developed by Styrax Pharma for pharmaceutical use, supporting the creation of diverse products in the industry.
Funding Insights of Styrax
Styrax has successfully raised a total of $2.75M through 1 strategic funding round. The most recent funding activity was a Series A round of $2.75 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $2.75M
- Total Rounds 1
- Last Round Series A β $2.75M
- First Round $2.75M
(Jul 2017)
- Investors Count 1
All 1 funding rounds of Styrax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | $2.75M | Series A | $8.8M | Arora Life Sciences | β |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2017 | $8.8M | β’β’β’β’β’β’β’β’ |
Last known valuation $8.8M (Jul 2017). 1 investors in total: 1 institutional.
Investors in Styrax
Styrax has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Arora Life Sciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified oral drugs are distributed by Arora Life Sciences. | Jammu, India |
Investor details for Styrax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Styrax Pharma Private Limited (Styrax)
Styrax Pharma Private Limited is the primary company behind Styrax. The board of Styrax Pharma Private Limited currently have 3 directors; the longest-serving is Suryadevara Venkateswara Rao, appointed in 2014. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Suryadevara Venkateswara Rao DIN 00363121 | Managing Director | 23 Jun 2014 | 12 yrs 5 mo | Styrax Pharma Private Limited |
| Sreenath Suryadevara DIN 07234232 | Director | 18 Apr 2019 | 7 yrs 7 mo | Styrax Pharma Private Limited |
| Lakshmi Devi Suryadevara DIN 06837476 | Director | 18 Apr 2019 | 7 yrs 7 mo | Styrax Pharma Private Limited |
People of Styrax
1 people are tracked at Styrax (1 in leadership); the tracked headcount is 260.
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for Styrax
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Styrax
Figures of Styrax Pharma Private Limited, the primary company behind Styrax, for FY 2024. Revenue was ₹260 Cr (+4% year on year). Net profit was ₹9.16 Cr (4% margin). EBITDA was ₹29.31 Cr (11% margin). Revenue has grown at a compounded annual rate of -3% over three years.
- ₹260 CrRevenue · FY 2024 · +4% YoY
- ₹9.16 CrNet profit · 4% margin
- ₹29.31 CrEBITDA · 11% margin
- ₹13.12 CrPaid-up capital
- 260Employees (provident fund records)
- -3%Revenue CAGR, 3 years
Balance sheet, profit and loss, cash flow and ratios of Styrax Pharma Private Limited are on its company page.
Detailed financial statements for Styrax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Styrax
3 dated milestones of Styrax across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Styrax is founded.
- Funding First funding round of $2.7M.
- Milestone Reaches Minicorn status.
Web traffic of Styrax
The website of Styrax (styraxpharma.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▲ 110.1% vs previous month
Top companies in Traditional Health & Nutrition
3 companies that operate in the same segment as Styrax (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Oral solid drug delivery systems are manufactured and developed. | 1985 | Mumbai, Maharashtra, India | USD 42.49 M | USD 72.52 M | 1,115 | |
Generic, semi-solid, and liquid dosage forms are manufactured. | 1990 | Bengaluru, Karnataka, India | USD 508.93 M | 4,050 | ||
Specialty generic pharmaceuticals and APIs are manufactured and marketed. | 1983 | Mumbai, Maharashtra, India | USD 6.44 B | 19,801 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Styrax
Styrax was founded in 1995 and raised its 1st funding round 22 years after it was founded.
Styrax is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Styrax is a funded company, having raised a total of $2.75M across 1 funding round to date. The company's 1st funding round was a Series A of $2.75M, raised on Jul 2017.
Styrax has 260 employees.
The primary company behind Styrax, Styrax Pharma Private Limited, reported revenue of βΉ260 Cr for FY 2024, up 4% year on year.
Manufacturer supplier of active pharmaceutical ingredients and intermediates. It offers a diverse range of active pharmaceutical ingredients and intermediates include Abacavir Sulphate, Emtricitabine USP, Lamivudine, Tenofovir Disoproxil Fumarate, Fluconazole, Itraconazole, Levocetirizine Dihydrochloride, Rifaximin, Duloxetine Hydrochloride and Eltrombopag.
Styrax offers APIs and Intermediates.
Styrax has 1 investor. Key investors include Arora Life Sciences.
The valuation of Styrax is $8.8M as of Jul 2017.
Styrax operates through Styrax Pharma Private Limited.
The legal entities of Styrax currently have 4 directors, including Sreenath Suryadevara, Lakshmi Devi Suryadevara, Mohit Mittal and others.